Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

Glenn J. Hanna; Naifa L. Busaidy; Nicole G. Chau; Lori J Wirth; Justine A Barletta; Antonio Calles; Robert I Haddad; Stefan Kraft; Maria E Cabanillas; Guilherme Rabinowits; Anne O'Neill; Sewanti A Limaye; Erik K Alexander; Francis D Moore; Krzysztof Misiukiewicz; Tom Thomas; Matthew A Nehs; Ellen Marqusee; Stephanie L Lee; Pasi A. Janne; Jochen H. Lorch

doi:10.1158/1078-0432.CCR-17-2297

Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

Glenn J. Hanna, Naifa L. Busaidy, Nicole G. Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits, Anne O'Neill, Sewanti A Limaye, Erik K Alexander, Francis D Moore, Krzysztof Misiukiewicz, Tom Thomas, Matthew A Nehs, Ellen Marqusee, Stephanie L Lee, Pasi A. JanneJochen H. Lorch

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Clinical Cancer Research
DOIs	https://doi.org/10.1158/1078-0432.CCR-17-2297
State	Published - Jan 4 2018
Externally published	Yes

Disciplines

Biology
Oncology

Access to Document

10.1158/1078-0432.CCR-17-2297License: Unspecified

Cite this

Hanna, G. J., Busaidy, N. L., Chau, N. G., Wirth, L. J., Barletta, J. A., Calles, A., Haddad, R. I., Kraft, S., Cabanillas, M. E., Rabinowits, G., O'Neill, A., Limaye, S. A., Alexander, E. K., Moore, F. D., Misiukiewicz, K., Thomas, T., Nehs, M. A., Marqusee, E., Lee, S. L., ... Lorch, J. H. (2018). Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-2297

Hanna, GJ, Busaidy, NL, Chau, NG, Wirth, LJ, Barletta, JA, Calles, A, Haddad, RI, Kraft, S, Cabanillas, ME, Rabinowits, G, O'Neill, A, Limaye, SA, Alexander, EK, Moore, FD, Misiukiewicz, K, Thomas, T, Nehs, MA, Marqusee, E, Lee, SL, Janne, PA & Lorch, JH 2018, 'Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study', Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-17-2297

@article{13ade85081dd43e88e99353c6cf8831b,

title = "Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study",

author = "Hanna, \{Glenn J.\} and Busaidy, \{Naifa L.\} and Chau, \{Nicole G.\} and Wirth, \{Lori J\} and Barletta, \{Justine A\} and Antonio Calles and Haddad, \{Robert I\} and Stefan Kraft and Cabanillas, \{Maria E\} and Guilherme Rabinowits and Anne O'Neill and Limaye, \{Sewanti A\} and Alexander, \{Erik K\} and Moore, \{Francis D\} and Krzysztof Misiukiewicz and Tom Thomas and Nehs, \{Matthew A\} and Ellen Marqusee and Lee, \{Stephanie L\} and Janne, \{Pasi A.\} and Lorch, \{Jochen H.\}",

note = "Purpose: Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer (TC). We evaluated the efficacy of everolimus in aggressive, radioactive iodine refractory (RAIR) TC and correlated tumor mutational profiling with response. Exploratory medullary and anaplastic TC cohorts were included.",

year = "2018",

month = jan,

day = "4",

doi = "10.1158/1078-0432.CCR-17-2297",

language = "American English",

journal = "Clinical Cancer Research",

}

TY - JOUR

T1 - Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

AU - Hanna, Glenn J.

AU - Busaidy, Naifa L.

AU - Chau, Nicole G.

AU - Wirth, Lori J

AU - Barletta, Justine A

AU - Calles, Antonio

AU - Haddad, Robert I

AU - Kraft, Stefan

AU - Cabanillas, Maria E

AU - Rabinowits, Guilherme

AU - O'Neill, Anne

AU - Limaye, Sewanti A

AU - Alexander, Erik K

AU - Moore, Francis D

AU - Misiukiewicz, Krzysztof

AU - Thomas, Tom

AU - Nehs, Matthew A

AU - Marqusee, Ellen

AU - Lee, Stephanie L

AU - Janne, Pasi A.

AU - Lorch, Jochen H.

N1 - Purpose: Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer (TC). We evaluated the efficacy of everolimus in aggressive, radioactive iodine refractory (RAIR) TC and correlated tumor mutational profiling with response. Exploratory medullary and anaplastic TC cohorts were included.

PY - 2018/1/4

Y1 - 2018/1/4

UR - http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-2297

U2 - 10.1158/1078-0432.CCR-17-2297

DO - 10.1158/1078-0432.CCR-17-2297

M3 - Article

JO - Clinical Cancer Research

JF - Clinical Cancer Research

ER -

Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study

Disciplines

Access to Document

Other files and links

Cite this